Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SPX-303 |
| Synonyms | |
| Therapy Description |
SPX-303 is a bispecific antibody targeting LILRB2 and CD274 (PD-L1), which potentially enhances antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2729). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SPX-303 | SPX303|SPX 303 | LILRB2 Antibody 12 PD-L1/PD-1 antibody 133 | SPX-303 is a bispecific antibody targeting LILRB2 and CD274 (PD-L1), which potentially enhances antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2729). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06259552 | Phase I | SPX-303 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303) | Recruiting | USA | 0 |